New combo aims to free ITP patients from lifelong medication
NCT ID NCT07278908
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding all-trans retinoic acid (ATRA) to the drug avatrombopag can help adults with immune thrombocytopenia (ITP) maintain normal platelet levels without needing ongoing treatment. About 248 participants who have not responded well to first-line therapy or have relapsed will be randomly assigned to receive either avatrombopag alone or avatrombopag plus ATRA for up to 24 weeks, followed by a tapering period. The main goal is to see how many people can stop all treatment and still have safe platelet counts at one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avatrombopag and all-trans retinoic acid
- What this could lead to
- If it works, this combination could help more people with ITP stop taking medication for a longer time, reducing the need for ongoing treatment.
- What could go wrong
- This is an early-to-mid stage trial with only 248 people, so results may not apply to everyone. The combination may cause side effects like headache, nausea, or liver issues, and it's not yet proven to be better than avatrombopag alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to boost platelets in ITP patients
- Stem cell trial for rare bleeding disorder pulled before it began
- Gene-Edited immune cells take on autoimmune blood diseases
- New drug OM336 aims to tame overactive immune system
- Promising ITP drug trial pulled before it even started
- New hope for teens with rare bleeding disorder: experimental drug enters final testing